Your browser doesn't support javascript.
loading
Enforced dimerization between XBP1s and ATF6f enhances the protective effects of the UPR in models of neurodegeneration.
Vidal, René L; Sepulveda, Denisse; Troncoso-Escudero, Paulina; Garcia-Huerta, Paula; Gonzalez, Constanza; Plate, Lars; Jerez, Carolina; Canovas, José; Rivera, Claudia A; Castillo, Valentina; Cisternas, Marisol; Leal, Sirley; Martinez, Alexis; Grandjean, Julia; Sonia, Donzelli; Lashuel, Hilal A; Martin, Alberto J M; Latapiat, Veronica; Matus, Soledad; Sardi, S Pablo; Wiseman, R Luke; Hetz, Claudio.
Afiliação
  • Vidal RL; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile. Electronic address: rene.vidal@umayor.cl.
  • Sepulveda D; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
  • Troncoso-Escudero P; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Program of Cellular and Molecular Biology, Institute of Biomedical S
  • Garcia-Huerta P; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
  • Gonzalez C; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
  • Plate L; Department of Chemistry, Department of Biological Sciences, Vanderbilt University, Nashville, TN, USA; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
  • Jerez C; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
  • Canovas J; Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
  • Rivera CA; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
  • Castillo V; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
  • Cisternas M; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
  • Leal S; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
  • Martinez A; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
  • Grandjean J; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
  • Sonia D; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
  • Lashuel HA; Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
  • Martin AJM; Laboratorio de Biología de Redes, Centro de Genómica y Bioinformática, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.
  • Latapiat V; Laboratorio de Biología de Redes, Centro de Genómica y Bioinformática, Facultad de Ciencias, Universidad Mayor, Santiago, Chile.
  • Matus S; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Fundacion Ciencia Vida, Santiago 7780272, Chile; Facultad de Medicina y Ciencia, Universidad San Sebastián, Providencia 7510157, Santiag
  • Sardi SP; Rare and Neurological Diseases Therapeutic Area, Sanofi, 49 New York Avenue, Framingham, MA, USA.
  • Wiseman RL; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
  • Hetz C; Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile; Buck Institute for Re
Mol Ther ; 29(5): 1862-1882, 2021 05 05.
Article em En | MEDLINE | ID: mdl-33545358
ABSTRACT
Alteration to endoplasmic reticulum (ER) proteostasis is observed in a variety of neurodegenerative diseases associated with abnormal protein aggregation. Activation of the unfolded protein response (UPR) enables an adaptive reaction to recover ER proteostasis and cell function. The UPR is initiated by specialized stress sensors that engage gene expression programs through the concerted action of the transcription factors ATF4, ATF6f, and XBP1s. Although UPR signaling is generally studied as unique linear signaling branches, correlative evidence suggests that ATF6f and XBP1s may physically interact to regulate a subset of UPR target genes. In this study, we designed an ATF6f/XBP1s fusion protein termed UPRplus that behaves as a heterodimer in terms of its selective transcriptional activity. Cell-based studies demonstrated that UPRplus has a stronger effect in reducing the abnormal aggregation of mutant huntingtin and α-synuclein when compared to XBP1s or ATF6 alone. We developed a gene transfer approach to deliver UPRplus into the brain using adeno-associated viruses (AAVs) and demonstrated potent neuroprotection in vivo in preclinical models of Parkinson's disease and Huntington's disease. These results support the concept in which directing UPR-mediated gene expression toward specific adaptive programs may serve as a possible strategy to optimize the beneficial effects of the pathway in different disease conditions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Fator 6 Ativador da Transcrição / Resposta a Proteínas não Dobradas / Proteína 1 de Ligação a X-Box Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Neurodegenerativas / Fator 6 Ativador da Transcrição / Resposta a Proteínas não Dobradas / Proteína 1 de Ligação a X-Box Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article